BRAF and thyroid gland carcinoma: A better understanding of these relations may be crucial in the development and improvement of the most promising thyroid carcinoma therapy, namely, small-molecule tyrosine kinase inhibitors (TKIs), such as Sorafenib, which is a BRAF-inhibitor that was already approved for radioiodine-resistant metastatic differentiated thyroid cancer therapy [57,58].